Biotechnology

Forum Markets

Forum Markets Launches Ethereum-Based Tokenized RWA Platform Strategy, Targets $175M AUM by 2026

Forum Markets CEO McAndrew Rudisill to Attend Benchmark Digital Asset Summit on May 27

Forum Markets released FY2026 Q1 earnings on May 14 Pre-Market EST, actual revenue USD 2.859 M (forecast USD 1.4 M), actual EPS USD -3.5804 (forecast USD -0.22)

Forum Markets to Release FY2026 Q1 Earnings on May 14 Pre-Market EST, Forecast Revenue USD 1.4 M, EPS USD -0.22

Forum Markets released FY2025 Q4 earnings on March 31 Pre-Market EST, actual revenue USD 2.437 M, actual EPS USD -12.048

Forum Markets released FY2025 Annual Earnings on March 31 Pre-Market (EST), actual revenue USD 6.547 M (forecast USD 16.64 M), actual EPS USD -55.177

Forum Markets FY2025 Q4 Earnings Release on March 31, 2026 Pre-Market EST

Forum Markets released FY2024 Q3 earnings on November 14, 2025 (EST) with actual revenue of USD 0 and EPS of USD -8.5333

Forum Markets released FY2025 9 Months Earnings on November 14, 2025 (EST) with actual revenue of USD 4.11M and EPS of USD -27.179

Forum Markets released FY2024 9 Months Earnings on November 14 (EST), actual revenue USD 0, actual EPS USD -25.2333

Forum Markets released FY2025 Q3 earnings on November 14 (EST), actual revenue USD 4.11 M, actual EPS USD -17.4542

Forum Markets released FY2025 Q2 earnings on July 23, 2025 (EST) with actual revenue of USD 0 and EPS of USD -3.0248

FORUM MARKETS INCORPORATED released FY2025 Semi-Annual Earnings on July 23 (EST) with actual revenue of USD 0 and EPS of USD -8.8468

Forum Markets released FY2024 Semi-Annual earnings on July 23, 2025 (EST) with actual revenue of USD 0 and EPS of USD -14.2

FRMM.US released FY2024 Q2 earnings on July 23, 2025 (BJT), with actual revenue of USD 0 and EPS of USD 0.0999

Forum Markets Incorporated released FY2025 Q1 earnings on May 15 (EST), actual revenue USD 0, actual EPS USD -6.6999

Forum Markets released FY2024 Q1 earnings on May 15 (EST), actual revenue USD 0, actual EPS USD -16.7999

Forum Markets released FY2023 Annual Earnings on March 31 (EST), actual revenue USD 0 (forecast USD 2.855 M), actual EPS USD -525.8999

Forum Markets released FY2024 Q4 earnings on March 31 (EST), actual revenue USD 0, actual EPS USD -109.509

Forum Markets released FY2023 Q4 earnings on March 31 (EST), actual revenue USD 0, actual EPS USD -19.7415

InMed Pharmaceuticals

AMPLITECH GROUP INC. USD0.001 S/R 20/11/26 SER B

Amesite

CN Energy

AMPLITECH GROUP INC. COM USD0.001 (S/R 18/07/2026)

NextNRG

Meiwu Tech

Generation Income Properties

MetaVia

OceanPal

FRMM

Forum Markets reported Q1 2026 revenue of $2.9 million with a net loss of $77.5 million. The company ended the quarter with $65.9 million in cash. Highlights include a $25 million share repurchase and the launch of an AI infrastructure financing program. The company aims for $100M–$175M in AUM by year-end 2026 and targets $250M–$300M by 2027, expecting 50%–100% revenue growth in 2027.

TradingView

Forum Markets reports Q1 2026 revenue $2.9M, net loss $77.5M and $65.9M cash

Forum Markets GAAP EPS of $0.06 beats by $0.28, revenue of $2.9M beats by $1.5M

businessinsider

Forum Markets GAAP EPS of $0.06 beats by $0.28, revenue of $2.9M beats by $1.5M

Earnings Watch

Forum Markets | 8-K: FY2026 Q1 Revenue: USD 2.859 M

Purcell & Lefkowitz LLP is investigating Forum Markets, Incorporated (NASDAQ: FRMM) on behalf of its shareholders to determine if the company's directors breached their fiduciary duties related to recent corporate actions. Shareholders seeking more information about their rights can contact the firm for assistance.

prnewswire

10:20 ETSHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Forum Markets, Incorporated (NASDAQ: FRMM)

Clear Street has initiated coverage of Forum Markets, Inc. (Nasdaq: FRMM) with a Buy rating and a price target of $11.00 per share, indicating a potential upside of approximately 145%. The report highlights Forum's strategy of tokenizing real-world assets and its revenue-generating initiatives. CEO McAndrew Rudisill welcomed the coverage, emphasizing the company's progress in asset origination and infrastructure development. The report also notes Forum's shares trade at about 0.46x Clear Street's net asset value estimate. Investors can access the full report through Clear Street's channels.

StockTitan

Forum Announces Initiation of Analyst Coverage by Clear Street | FRMM Stock News

Forum Markets has repurchased and cancelled approximately 5.65 million shares as part of its reinitiated buyback program, spending around $24.07 million. The program, effective from April 15, 2026, was publicly announced on April 17, 2026. The average repurchase price was about $4.26 per share. After these cancellations, about 14.65 million shares remain outstanding as of April 28, 2026. Future repurchases may continue depending on legal, market, and financial conditions, as well as Board discretion.

Forum Markets updates repurchase program, cancels 5.65M shares totaling $24.1M

Forum Markets pre-market down 8.61%; Fold pre-market up 8.33%; Psyence Biomedical pre-market up 91.18%; Theriva Biologics pre-market up 70.61%; Clearmind Medicine pre-market up 54.25%

Price Alert

Fold

Pre-market hot trades in US stocks: Forum Markets down 8.61% in pre-market; Fold up 8.33% in pre-market

Forum Markets (FRMM) announced a share buyback program and a strategic review on April 17, 2026, aiming to align its market capitalization with its intrinsic value. The board authorized buybacks exceeding typical limits and formed a special committee to explore strategic options, including mergers, acquisitions, or capital returns. Clear Street Investment Banking will assist in valuation and potential transactions. Analysts rate FRMM stock as a Buy with a $5.00 target, though concerns about financial performance and technical setup persist, leading to a Neutral rating from TipRanks’ AI Analyst.

Tip Ranks

Clear Street

Forum Markets Launches Share Buyback and Strategic Review

ENVB

ALGS

CMND

NOTV

IFRX

On Friday, several health care stocks experienced significant movements. Psyence Biomedical (PBM) surged 40.5% to $8.25, while InflaRx (IFRX) rose 25.85% to $1.51. Other gainers included Forum Markets (FRMM) up 22.78% to $2.91, and Bristol-Myers Squibb (CELGR) increasing 22.35% to $0.11. Conversely, Enveric Biosciences (ENVB) fell 23.3% to $1.80, with Clearmind Medicine (CMND) down 13.57% to $0.72. Aligos Therapeutics (ALGS) decreased 12.54% to $6.70, and Inotiv (NOTV) dropped 10.54% to $0.26.

Forum Markets(FRMM.US)

Forum Markets reports Q1 2026 revenue $2.9M, net loss $77.5M and $65.9M cash

Forum Markets GAAP EPS of $0.06 beats by $0.28, revenue of $2.9M beats by $1.5M

Forum Markets | 8-K: FY2026 Q1 Revenue: USD 2.859 M

10:20 ETSHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Forum Markets, Incorporated (NASDAQ: FRMM)

Forum Announces Initiation of Analyst Coverage by Clear Street | FRMM Stock News

Forum Markets updates repurchase program, cancels 5.65M shares totaling $24.1M

Pre-market hot trades in US stocks: Forum Markets down 8.61% in pre-market; Fold up 8.33% in pre-market

Forum Markets Launches Share Buyback and Strategic Review

10 Health Care Stocks Moving In Friday's Intraday Session